PE20242355A1 - Composiciones que contienen fexofenadina - Google Patents

Composiciones que contienen fexofenadina

Info

Publication number
PE20242355A1
PE20242355A1 PE2024001517A PE2024001517A PE20242355A1 PE 20242355 A1 PE20242355 A1 PE 20242355A1 PE 2024001517 A PE2024001517 A PE 2024001517A PE 2024001517 A PE2024001517 A PE 2024001517A PE 20242355 A1 PE20242355 A1 PE 20242355A1
Authority
PE
Peru
Prior art keywords
fexofenadine
compositions containing
spray
zwitterion
containing fexofenadine
Prior art date
Application number
PE2024001517A
Other languages
English (en)
Spanish (es)
Inventor
Daniela Maldonado Cavalari
Maxime Liboureau
Chakib Zaghloul
Original Assignee
Opella Healthcare Group Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opella Healthcare Group Sas filed Critical Opella Healthcare Group Sas
Publication of PE20242355A1 publication Critical patent/PE20242355A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2024001517A 2021-12-29 2021-12-29 Composiciones que contienen fexofenadina PE20242355A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2021/000916 WO2023126637A1 (en) 2021-12-29 2021-12-29 Compositions containing fexofenadine

Publications (1)

Publication Number Publication Date
PE20242355A1 true PE20242355A1 (es) 2024-12-16

Family

ID=80122351

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024001517A PE20242355A1 (es) 2021-12-29 2021-12-29 Composiciones que contienen fexofenadina

Country Status (13)

Country Link
US (1) US20250082623A1 (cg-RX-API-DMAC10.html)
EP (1) EP4456880B1 (cg-RX-API-DMAC10.html)
JP (1) JP7826492B2 (cg-RX-API-DMAC10.html)
KR (1) KR20240136358A (cg-RX-API-DMAC10.html)
CN (1) CN118715004A (cg-RX-API-DMAC10.html)
AR (1) AR128113A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021480621A1 (cg-RX-API-DMAC10.html)
CA (1) CA3242293A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024009774A2 (cg-RX-API-DMAC10.html)
ES (1) ES3069308T3 (cg-RX-API-DMAC10.html)
MX (1) MX2024008242A (cg-RX-API-DMAC10.html)
PE (1) PE20242355A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023126637A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026074306A1 (en) 2024-10-03 2026-04-09 Opella Healthcare Group Sas Chewable fexofenadine tablets

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
DOP2006000274A (es) 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
FR2959130A1 (fr) 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
CN102512389B (zh) 2011-12-27 2013-08-21 天津市嵩锐医药科技有限公司 非索非那定盐酸盐口腔崩解药物组合物
KR101761983B1 (ko) * 2014-08-25 2017-08-07 아주대학교산학협력단 구강내 속붕해 필름 조성물 및 그 제조방법
CN105997910A (zh) 2016-06-09 2016-10-12 北京化工大学 一种掩味制剂及其制备方法

Also Published As

Publication number Publication date
US20250082623A1 (en) 2025-03-13
AU2021480621A1 (en) 2024-07-18
EP4456880A1 (en) 2024-11-06
ES3069308T3 (en) 2026-06-05
MX2024008242A (es) 2024-07-19
EP4456880B1 (en) 2026-03-18
JP7826492B2 (ja) 2026-03-09
KR20240136358A (ko) 2024-09-13
JP2024546513A (ja) 2024-12-24
AR128113A1 (es) 2024-03-27
EP4456880C0 (en) 2026-03-18
CA3242293A1 (en) 2023-07-06
WO2023126637A1 (en) 2023-07-06
CO2024009774A2 (es) 2024-08-08
CN118715004A (zh) 2024-09-27

Similar Documents

Publication Publication Date Title
CO2019000069A2 (es) Agentes antivirales contra la hepatitis b
UY37997A (es) Agentes antivirales contra la hepatitis b
CO2018010748A2 (es) Agentes antivirales contra la hepatitis b
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
UY38059A (es) Heterociclos sustituidos como agentes antivirales
CO2020002980A2 (es) Agentes antivirales contra la hepatitis b.
PE20151593A1 (es) Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano
CR11137A (es) Valvulas prosteticas de corazon
ECSP11011398A (es) Inhibidores de beta-secretasa
HN2010002121A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak
CL2009001766A1 (es) Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica.
ECSP17085669A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
UY38383A (es) Heterociclos funcionalizados como agentes antivirales
MX2016014771A (es) Forma de dosificacion oralmente desintegrante para administracion de avanafil, y metodos de fabricacion y uso asociados.
EA201490395A1 (ru) Способ получения фармацевтических композиций, содержащих финголимод
MX2018009500A (es) Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus metodos de preparacion y usos de la sal de maleato y formas cristalinas.
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
PE20141155A1 (es) Analogos del acido epoxi-eicosatrienoico y metodos para hacer y de uso del mismo
CL2015000869A1 (es) Composiciones para el cuidado bucal.
ECSP12012180A (es) Composición que comprende el péptido amiloide beta 1-6 acoplado a una partícula similar a virus y un auxiliar
CY1119594T1 (el) Φαρμακευτικη και προφυλακτικη φαρμακευτικη συνθεση για την στοματικη υγιεινη
CO6300935A2 (es) Formulaciones orales e inyectables de compuestos de tetraciclina
CL2025000161A1 (es) Compuestos cíclicos y métodos de utilización de estos.
MX2025013493A (es) Derivado de tiazol inhibidor, y metodo de preparacion del mismo y uso del mismo